Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/25438
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3646]
- IOC - Artigos de Periódicos [12973]
Metadata
Show full item record15
CITATIONS
15
Total citations
5
Recent citations
2.37
Field Citation Ratio
0.64
Relative Citation Ratio
COMPARISON OF HEPATITIS B VIRUS INFECTION IN HIV-INFECTED AND HIV-UNINFECTED PARTICIPANTS ENROLLED IN A MULTINATIONAL CLINICAL TRIAL: HPTN 052
Author
Greer, Amy E.
Ou, San-San
Wilson, Ethan
Piwowar-Manning, Estelle
Forman, Michael S.
McCauley, Marybeth
Gamble, Theresa
Ruangyuttikarn, Cholticha
Hosseinipour, Mina C.
Kumarasamy, Nagalingeswaran
Nyirenda, Mulinda
Grinsztejn, Beatriz
Pilotto, Jose Henrique
Kosashunhanan, Natthapol
Melo, Marineide Gonçalves de
Makhema, Joseph
Akelo, Victor
Panchia, Ravindre
Badal-Faesen, Sharlaa
Chen, Ying Q.
Cohen, Myron S.
Eshleman, Susan H.
Thio, Chloe L.
Valsamakis, Alexandra
Ou, San-San
Wilson, Ethan
Piwowar-Manning, Estelle
Forman, Michael S.
McCauley, Marybeth
Gamble, Theresa
Ruangyuttikarn, Cholticha
Hosseinipour, Mina C.
Kumarasamy, Nagalingeswaran
Nyirenda, Mulinda
Grinsztejn, Beatriz
Pilotto, Jose Henrique
Kosashunhanan, Natthapol
Melo, Marineide Gonçalves de
Makhema, Joseph
Akelo, Victor
Panchia, Ravindre
Badal-Faesen, Sharlaa
Chen, Ying Q.
Cohen, Myron S.
Eshleman, Susan H.
Thio, Chloe L.
Valsamakis, Alexandra
Affilliation
Johns Hopkins Hospital. Department of Pathology. Baltimore, MD, USA.
Vaccine and Infectious Disease Division. Fred Hutchinson Cancer Research Center. Seattle, WA, USA.
Vaccine and Infectious Disease Division. Fred Hutchinson Cancer Research Center. Seattle, WA, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, USA.
Johns Hopkins Hospital. Department of Pathology. Baltimore, MD, USA.
FHI 360. Washington, DC, USA.
FHI 360. Durham, NC, USA.
Chiang Mai University. Research Institute for Health Sciences. Chaing Mai, Thailand.
University of North Carolina at Chapel Hill. Chapel Hill, NC, USA / UNC Project-Malawi. Institute for Global Health and Infectious Diseases. Lilongwe, Malawi.
YRGCARE Medical Centre. VHS. Chennai, India.
College of Medicine-Johns Hopkins Project. Blantyre, Malawi.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Geral de Nova Iguaçu. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Research Institute for Health Sciences. Chiang Mai University. Chaing Mai, Thailand.
Hospital Nossa Senhora da Conceição. Porto Alegre, RS, Brasil.
Botswana Harvard AIDS Institute. Gaborone, Botswana.
Kenya Medical Research Institute. Kisumu, Kenya / Center for Disease Control. Kisumu, Kenya.
University of the Witwatersrand. Perinatal HIV Research Unit. Soweto HPTN CRS. Soweto, South Africa.
University of Witwatersrand. Johannesburg, South Africa.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, WA, USA.
University of North Carolina at Chapel Hill. Department of Medicine. Chapel Hill, NC, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, MD, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, MD. USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, MD, USA.
Vaccine and Infectious Disease Division. Fred Hutchinson Cancer Research Center. Seattle, WA, USA.
Vaccine and Infectious Disease Division. Fred Hutchinson Cancer Research Center. Seattle, WA, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, USA.
Johns Hopkins Hospital. Department of Pathology. Baltimore, MD, USA.
FHI 360. Washington, DC, USA.
FHI 360. Durham, NC, USA.
Chiang Mai University. Research Institute for Health Sciences. Chaing Mai, Thailand.
University of North Carolina at Chapel Hill. Chapel Hill, NC, USA / UNC Project-Malawi. Institute for Global Health and Infectious Diseases. Lilongwe, Malawi.
YRGCARE Medical Centre. VHS. Chennai, India.
College of Medicine-Johns Hopkins Project. Blantyre, Malawi.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Geral de Nova Iguaçu. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Research Institute for Health Sciences. Chiang Mai University. Chaing Mai, Thailand.
Hospital Nossa Senhora da Conceição. Porto Alegre, RS, Brasil.
Botswana Harvard AIDS Institute. Gaborone, Botswana.
Kenya Medical Research Institute. Kisumu, Kenya / Center for Disease Control. Kisumu, Kenya.
University of the Witwatersrand. Perinatal HIV Research Unit. Soweto HPTN CRS. Soweto, South Africa.
University of Witwatersrand. Johannesburg, South Africa.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, WA, USA.
University of North Carolina at Chapel Hill. Department of Medicine. Chapel Hill, NC, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, MD, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, MD. USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, MD, USA.
Abstract
Objective: Data comparing hepatitis B virus (HBV) infection in HIV-infected [HIV(+)], and HIV-uninfected [HIV(-)] individuals recruited into the same study are limited. HBV infection status and chronic hepatitis B (cHB) were characterized in a multinational clinical trial: HIV Prevention Trials Network (HPTN 052). Method: HBV infection status at enrollment was compared between HIV(+) (N = 1241) and HIV(-) (N = 1232) from 7 HBV-endemic countries. Hepatitis B e antigen and plasma HBV DNA were determined in cHB. Median CD4, median plasma HIV RNA, and prevalence of transaminase elevation were compared in HIV(+) with and without cHB. Significance was assessed with χ, Fisher exact, and median tests. Results: Among all participants, 33.6% had HBV exposure without cHB (8.9% isolated HBV core antibody, "HBcAb"; 24.7% HBcAb and anti-HB surface antibody positive, "recovered"), 4.3% had cHB, 8.9% were vaccinated, and 53.5% were uninfected. Data were similar among HIV(+) and HIV(-) except for isolated HBcAb, which was more prevalent in HIV(+) than HIV(-) [10.1% vs. 7.7%, P = 0.046]. Median HBV DNA trended higher in HIV(+) than in HIV(-). In HIV(+) with cHB versus those without cHB, transaminase elevations were more prevalent (alanine aminotransferase ≤ grade 2, 12% vs. 5.2%, P = 0.037; aspartate aminotransferase ≤ grade 2, 26% vs. 6.0%, P < 0.001), CD4 trended lower, and HIV RNA was similar. Conclusions: HBV infection status did not differ by HIV infection status. HIV co-infection was associated with isolated HBcAb and a trend of increased HBV DNA. In HIV, cHB was associated with mild transaminase elevations and a trend toward lower CD4.
Share